
NovaBridge Appoints Mark Hagler [USNA '89] as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
Published on April 29, 2026
NovaBridge Biosciences (Nasdaq: NBP) announced on April 22, 2026, that Mark Hagler has been appointed President and Chief Commercial Officer, a move aimed at strengthening the company’s leadership and advancing its commercial strategy to maximize the value of its pipeline Markets Insider.
About Mark Hagler
Hagler is a seasoned biotechnology commercial executive with over 25 years of experience building, scaling, and transforming biopharmaceutical and specialty pharmaceutical businesses Markets Insider. He has a strong reputation and track record in high-value pharmaceutical markets, particularly oncology and ophthalmology.
BZ '89!
